English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

Innovent Buys from the Chinese Science Academy an Anti-Cancer drug for $457 Million

Sep. 5, 2017

Innovent Biologics announced a USD457 million acquisition of the exclusive global rights for Indoleamine 2, a 3-dioxygenase (IDO) inhibitor, developed by Shanghai Institute of Organic Chemistry (SIOC).

Innovent is planning to combine the IDO therapy in its Phase-3 PD-1 program.